Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150603 | 0.89 | CNR1 (0.44) | KMT2AMEN1LMNAHPGDALDH1A1 | |
| SCHEMBL2013388 | 0.89 | THRB (0.39) | THRBLMNAALDH1A1MAPTTDP1 | |
| SCHEMBL10150960 | 0.88 | PDE10A (0.42) | THRBKMT2AMEN1LMNAMAPT | |
| SCHEMBL1979905 | 0.82 | P2RX7 (0.43) | — | |
| SCHEMBL10150590 | 0.82 | PDE10A (0.42) | THRBKMT2ALMNAMAPT | |
| SCHEMBL1975060 | 0.81 | PPARG (0.40) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL2015522 | 0.79 | BCL2 (0.42) | THRBKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL2010877 | 0.78 | L3MBTL1 (0.48) | KMT2AMEN1HPGDALDH1A1MAPT | |
| SCHEMBL1976362 | 0.77 | WDR91 (0.37) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1978497 | 0.75 | KCNA3 (0.43) | KMT2AMEN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207347-B2 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| WO-2011072691-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | KCNK3, GRIK3, KCND3 | THRB 2186/4885KMT2A 1757/4885MEN1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.